Explore how INB.bio scales in emerging markets with local teams, 100+ products, and full-cycle operations beyond saturated regions. Over the past six years, the company has developed local teams, ...
Zacks Small Cap Research on MSN
INAB: Introducing INB-600, A γδ T Cell Engager Platform
Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc. (NASDAQ:INAB) reported 2024 financial ...
INB.bio Launches 2026 Growth Strategy With New Market Entries Across Africa, MENA and Southeast Asia
BERLIN, March 22, 2026 (GLOBE NEWSWIRE)-- Global demand for wellness products is climbing steadily, with the industry reaching a record $6.8 trillion and projected to hit $9.8 trillion by 2029, and a ...
IN8bio announces INB-619, a novel γδ T cell therapy platform targeting CD19, showing promise in B cell depletion with reduced side effects. IN8bio, Inc. has announced the launch of its innovative γδ T ...
INB-200 shows significantly improved progression-free survival in glioblastoma patients, with favorable safety profile and no serious toxicities reported. Repeated doses of INB-200 demonstrated an ...
INB-100 continues to demonstrate durable complete remissions (CR) with no relapses observed in any acute myeloid leukemia (AML) patients including those with high-risk disease after a median follow-up ...
Furthermore, IN8bio has announced encouraging results from its Phase 1 trial of INB-200, a therapy for glioblastoma, a type of brain cancer. The study found that 50% of patients receiving multiple ...
Top Priority Clinical Program: Working to drive significant value creation with INB-100 for AML; ongoing trial is actively enrolling additional patients into the expansion cohort to further support ...
Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp ...
INB-100 treatment has achieved durable 100% complete remission (CR) in treated patients, including high-risk acute myeloid leukemia (AML) patients and a patient with acute lymphoblastic leukemia (ALL) ...
Indústrias Nucleares do Brasil has signed a contract with Amazônia Azul Technologias de Defesa SA (Amazul) to provide engineering services for the second phase of the uranium enrichment plant at INB's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results